Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BOLD vs SNY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SNY Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 10–0 Matrix Metrics)

SNY Overall Winner 6-Pillar Tally: BOLD 0 – 5 SNY (1 Tie) Matrix Metrics: BOLD 0 – 10 SNY

As of Nov 20, 2026, Sanofi (SNY) is the stronger overall head-to-head candidate over Boundless Bio, Inc. (BOLD) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BOLD carries a Unified Composite Score of 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin), whereas SNY carries 40.3/100 (SELL) at $46.52 (8.6x Forward P/E, 22.3% operating margin).

  • Defensive Composite Rating Caution: Although SNY compares more favorably head-to-head, both BOLD (36.8/100 SELL) and SNY (40.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: BOLD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile SNY trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BOLD vs SNY
BOLD NASDAQ
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.08β · 28% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.6%), weak momentum, RSI 35
RSI-14: 35.0 · SMA20: $2.43 · SMA50: $2.52
SNY NASDAQ Head-to-Head Winner
Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
Pharmaceutical Preparations
$46.52
+1.0% 1D
Market Cap $110.6B
TTM Revenue $30.1B
Forward P/E 8.6x
Beta / 30D Vol 0.20β · 26% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 32.0 Fund 43.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.6% over 20 days), RSI 58
RSI-14: 57.5 · SMA20: $46.15 · SMA50: $43.08

6-Pillar Scorecard Institutional Category Breakdown (BOLD 0 – 5 SNY)

Columns: Metric · BOLD · SNY
1. Valuation Multiples SNY
Forward P/E N/M 8.6x
Trailing P/E N/M 22.9x
PEG Ratio N/M 2.90x
EV / Revenue N/M 3.7x
2. Growth & Scale SNY
Revenue Growth (YoY) +0.0% +15.7%
Earnings Growth (YoY) +0.0% +9.4%
TTM Revenue (USD) N/A $30.1B
Market Cap $56.2M $110.6B
3. Profitability & Quality SNY
Gross Margin N/A 74.3%
Operating Margin 0.0% 22.3%
Net Profit Margin 0.0% 8.2%
Return on Equity (ROE) -64.6% 5.7%
4. Balance Sheet & Cash Flow SNY
Cash Generation (TTM) -$48M $8.72B EBITDA
Cash Flow Margin N/A 29.0% EBITDA Mgn
Net Cash / Leverage $31M Net Debt (0.56x D/E) $34.11 Book/Sh · 5.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 22.0% (43rd %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat SNY
OpEx & R&D Intensity N/A 52.0% of Rev ($15.6B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BOLD (0) vs SNY (10)
Institutional Metric BOLD SNY Criterion Row Edge
Market Capitalization
Scale
$56.2M $110.6B Larger Scale SNY
Trailing P/E Ratio
Valuation
N/M 22.9x Lower Multiple SNY
Forward P/E Ratio
Valuation
N/M 8.6x Lower Multiple SNY
Revenue Growth (YoY)
Growth
+0.0% +15.7% Higher Growth SNY
Operating Margin (TTM)
Profitability
0.0% 22.3% Higher Margin SNY
Net Profit Margin
Profitability
0.0% 8.2% Higher Margin SNY
Return on Equity (ROE)
Capital Efficiency
-64.6% 5.7% Higher ROE SNY
52-Week Range Position
Momentum
62% ($1–$3) 65% ($39–$51) Stronger Trend SNY
Beta / 30D Volatility
Risk Regime
-0.08β · 28% Vol 0.20β · 26% Vol Lower Realized Risk SNY
Unified Institutional Score
Composite Signal
36.8 / 100 (SELL) 40.3 / 100 (SELL) Higher Composite SNY
Trailing 12M Revenue (USD)
Operating Scale
N/A $30.1B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 74.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 2.90x PEG · 3.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$48M ($31M Net Debt (0.56x D/E)) $8.72B EBITDA ($34.11 Book/Sh · 5.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SNY +15.79 pp
BOLD: -4.92% · SNY: +10.87%
3M Horizon SNY +23.44 pp
BOLD: -21.62% · SNY: +1.82%
6M Horizon BOLD +56.08 pp
BOLD: +61.11% · SNY: +5.03%
1Y Horizon BOLD +107.86 pp
BOLD: +101.74% · SNY: -6.12%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BOLD vs SNY. Trailing 12-month operating profitability (BOLD 0.0% vs SNY 22.3%) and valuation multiples (BOLD N/M vs SNY 8.6x Forward P/E) are benchmarked directly in Pillar 4 below.

BOLD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-64.6% · N/M
SNY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$30.1B
Gross Margin74.3%
Op. Margin22.3%
ROE / Fwd P/E5.7% · 8.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BOLD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BOLD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SNY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.0%
IV Percentile 43rd %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BOLD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SNY Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $110.6B market capitalization and 22.3% operating margin.
OpEx & R&D Reinvestment 52.0% of Rev ($15.6B)
90D Engineering Disclosures 0 Published

Investor FAQ BOLD vs SNY Key Questions & Quantitative Answers

As of Nov 20, 2026, Sanofi (SNY) is the stronger overall head-to-head candidate over Boundless Bio, Inc. (BOLD) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BOLD carries a Unified Composite Score of 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin), whereas SNY carries 40.3/100 (SELL) at $46.52 (8.6x Forward P/E, 22.3% operating margin). Defensive Composite Rating Caution: Although SNY compares more favorably head-to-head, both BOLD (36.8/100 SELL) and SNY (40.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: BOLD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0); meanwhile SNY trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SNY leads the Growth & Scale pillar: BOLD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SNY at +15.7% YoY revenue growth and +9.4% YoY earnings growth on $30.1B TTM revenue (74.3% gross margin, 22.3% operating margin). On trailing 12-month operating scale, BOLD generates N/A in USD-normalized revenue versus $30.1B for SNY. In operating R&D and SG&A reinvestment, BOLD deploys N/A (0 90-day corporate R&D disclosures) versus 52.0% of Rev ($15.6B) (0 disclosures) for SNY.

SNY screens cheaper on headline valuation multiples. BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SNY trades at 8.6x Forward P/E, 22.9x Trailing P/E, 2.90x PEG, and 3.7x EV/Revenue (29.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BOLD (-64.6% ROE) versus SNY (5.7% ROE) capital efficiency.

In options market volatility and institutional positioning, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk). By comparison, SNY carries 22.0% implied volatility (43rd %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.20β · 26% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.